Connect your AI

Jazz Pharmaceuticals JAZZ Changes in unrecognized tax benefits

Changes in unrecognized tax benefits at other companies

Ionis PharmaceuticalsIONS

-3.2%—

Other financials

Income statement

Revenue$1.1B+19.1%

Operating income$336.6M+702%

Net income$293.1M+417%

EPS (diluted)$4.43+391%

Balance sheet

Cash & equivalents$667.5M-64.1%

Total debt$5.4B-0.1%

Total equity$4.5B+8.6%

Total assets$11.9B+2.8%

Cash flow

Operating cash flow$408.2M-5.0%

CapEx$19.7M+41.7%

Free cash flow$388.5M-6.6%

Valuation

Market cap$14.11B+54.4%

Enterprise value$18.85B+47.7%

P/S3.2×+0.9×

Profitability

Operating margin-11.9%-28.1pp

Net margin-8.9%-20.5pp

FCF margin28.6%-8.6pp

Returns & leverage

Return on equity-9.1%-21.2pp

Debt / equity1.2×-0.1×

Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies.

The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's changes in unrecognized tax benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Jazz Pharmaceuticals's changes in unrecognized tax benefits?: Jazz Pharmaceuticals (JAZZ) reported changes in unrecognized tax benefits of 0.9% in Q4 2025.
What does changes in unrecognized tax benefits mean?: The net change in the company's reserve for uncertain tax positions.
How do you interpret changes in unrecognized tax benefits?: An increase suggests higher tax risk or new tax disputes, while a decrease may indicate the resolution of past tax uncertainties.
How does changes in unrecognized tax benefits compare across companies?: Commonly reported by multinational corporations as 'Unrecognized Tax Benefits' or 'UTB' movements.